Short Interest in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Rises By 90.3%

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) was the target of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 457,500 shares, a growth of 90.3% from the December 15th total of 240,400 shares. Based on an average daily trading volume, of 3,640,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 3.2% of the company’s stock are sold short.

Wall Street Analysts Forecast Growth

Separately, Maxim Group reaffirmed a “hold” rating on shares of Virpax Pharmaceuticals in a research report on Wednesday, October 9th.

Virpax Pharmaceuticals Stock Performance

Shares of VRPX stock opened at $0.35 on Thursday. Virpax Pharmaceuticals has a 52-week low of $0.29 and a 52-week high of $5.48. The stock’s 50-day moving average price is $0.45 and its 200 day moving average price is $0.73.

Institutional Investors Weigh In On Virpax Pharmaceuticals

A hedge fund recently bought a new stake in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC acquired a new position in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned approximately 1.17% of Virpax Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 32.23% of the company’s stock.

About Virpax Pharmaceuticals

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.